Investigating a new treatment for wet age-related macular degeneration
Mechanistic study and therapeutic application of AIBP in AMD
This study is looking at a new way to help older adults with a serious eye condition called choroidal neovascularization, which can cause vision loss, by testing a protein that might improve treatment for those who haven't had success with current options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11018605 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapeutic approach for treating choroidal neovascularization (CNV), a severe form of age-related macular degeneration (AMD) that can lead to blindness in older adults. The study aims to explore the role of a protein called AIBP, which may help improve treatment outcomes for patients who do not respond well to current therapies. By enhancing cholesterol efflux and reducing inflammation, AIBP could potentially offer a more effective alternative to existing anti-VEGF treatments. Patients will be evaluated to determine how AIBP can be integrated into their treatment plans to address the limitations of current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with wet age-related macular degeneration who have not responded well to existing anti-VEGF therapies.
Not a fit: Patients with dry age-related macular degeneration or those who have not been diagnosed with any form of AMD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients suffering from wet age-related macular degeneration.
How similar studies have performed: Previous research has shown promise in using alternative therapies for AMD, but the specific application of AIBP in this context is relatively novel.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Fu, Yingbin — Baylor College of Medicine
- Study coordinator: Fu, Yingbin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.